Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To compare the progression-free survival (PFS) of the combination of pembrolizumab and epacadostat versus pembrolizumab and placebo (i.e. 2 treatment groups) based on RECIST 1.1 by independent central review; and To compare overall survival (OS) of the 2 treatment groups.
Inclusion criteria
- Melanoma